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Cucurbitacin-I (JSI-124) activates the JNK/c-Jun
signaling pathway independent of apoptosis and
cell cycle arrest in B Leukemic Cells
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Abstract
Background: Cucurbitacin-I (JSI-124) is potent inhibitor of JAK/STAT3 signaling pathway and has anti-tumor activity
in a variety of cancer including B cell leukemia. However, other molecular targets of JSI-124 beyond the JAK/STAT3
pathway are not fully understood.
Methods: BJAB, I-83, NALM-6 and primary CLL cells were treated with JSI-124 as indicated. Apoptosis was
measured using flow cytometry for accumulation of sub-G1 phase cells (indicator of apoptosis) and Annexin V/PI
staining. Cell cycle was analyzed by FACS for DNA content of G1 and G2 phases. Changes in phosphorylation and
protein expression of p38, Erk1/2, JNK, c-Jun, and XIAP were detected by Western blot analysis. STAT3 and c-Jun
genes were knocked out using siRNA transfection. VEGF expression was determined by mRNA and protein levels
by RT-PCR and western blotting. Streptavidin Pull-Down Assay was used to determine c-Jun binding to the AP-1
DNA binding site.
Results: Herein, we show that JSI-124 activates c-Jun N-terminal kinase (JNK) and increases both the expression
and serine phosphorylation of c-Jun protein in the B leukemic cell lines BJAB, I-83 and NALM-6. JSI-124 also
activated MAPK p38 and MAPK Erk1/2 albeit at lower levels than JNK activation. Inhibition of the JNK signaling
pathway failed to effect cell cycle arrest or apoptosis induced by JSI-124 but repressed JSI-124 induced c-Jun
expression in these leukemia cells. The JNK pathway activation c-Jun leads to transcriptional activation of many
genes. Treatment of BJAB, I-83, and NALM-6 cells with JSI-124 lead to an increase of Vascular Endothelial Growth
Factor (VEGF) at both the mRNA and protein level. Knockdown of c-Jun expression and inhibition of JNK activation
significantly blocked JSI-124 induced VEGF expression. Pretreatment with recombinant VEGF reduced JSI-124
induced apoptosis.
Conclusions: Taken together, our data demonstrates that JSI-124 activates the JNK signaling pathway independent
of apoptosis and cell cycle arrest, leading to increased VEGF expression.
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Background
Cucurbitacin-I (JSI-124) can be found in a variety of
plants that have been used for centuries as folk medi-
cines in Asia [1-3]. However, the molecular mechanisms
responsible for the various biological effects of JSI-124
have not been fully investigated. JSI-124 is a selective
dual inhibitor of phospho-JAK2 and phospho-STAT3 in
human breast cancer, lung cancer, neuroblastoma, and
murine melanoma cell lines [4,5]. This inhibitor has
been shown to exert anti-proliferative and anti-tumor
activity both in vivo and in vitro [2,4,6]. More recently
we have shown that JSI-124 can induce apoptosis and
cell cycle arrest in B-cell leukemia cell lines and in pri-
mary chronic lymphocytic leukemia (CLL) cells [7]. It is
possible that the anti-tumor effects of JSI-124 could be
explained by the inhibition of the constitutively activated
STAT3 signaling pathway in leukemia [7]. Independent
of its effects on STAT3, JSI-124 was shown to interfere
with LPA-mediated up-regulation of connective tissue
* Correspondence: gibsonsb@cc.umanitoba.ca
1Manitoba Institute of Cell Biology, Winnipeg, MB, Canada
Full list of author information is available at the end of the article
Ishdorj et al. BMC Cancer 2011, 11:268
http://www.biomedcentral.com/1471-2407/11/268
© 2011 Ishdorj et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
growth factor (CTGF), as demonstrated in wild type and
STAT3 knock-out mouse embryonic fibroblasts [8].
Thus far, these different activities of JSI-124 has not
been investigated in parallel, and the specificity of the
compound as an inhibitor of STAT3 signaling has not
been defined in relation to the effects of the drug on
other signaling pathways.
Chemotherapeutic drugs often induce a stress
response in cancer cells. One of the early stress response
pathways is the c-Jun N-terminal kinase (JNK) pathway
[9]. JNK is a member of the mitogen activated protein
kinase (MAPK) family that includes p38 and Erk1/2.
The JNK pathway is activated by a variety of stimuli
including UV radiation and DNA damaging agents. It
has been demonstrated that this pathway could contri-
bute to apoptosis and regulation of gene expression
[9,10]. JNK regulates gene expression though phosphor-
ylation of c-Jun and activation of the AP-1 complex
[10]. These genes regulate many functions including cell
survival, cell death, and angiogenesis [10].
Vascular endothelial growth factor (VEGF), known as
VEGF-A, belongs to the cysteine-knot superfamily of
growth factors, which is the crucial regulator of angio-
genesis [11]. Angiogenesis is a complex multistep pro-
cess, which can contribute to cancer progression, tumor
growth and metastasis [12,13]. Although VEGF is a
cytokine that regulates normal hematopoiesis, VEGF can
act as an auto-and paracrine stimulator of cell survival
and angiogenesis in hematological malignancies such as
chronic myelogenous leukemia and chronic lymphocytic
leukemia (CLL) [14,15]. VEGF expression has been
related to induction of the c-Jun N-terminal kinase
(JNK) signaling pathway with activation of transcription
factors such as HIF-1 [16,17]. We and others have pre-
viously demonstrated that lysophosphatidic acid (LPA)
increases VEGF expression involving JNK and transcrip-
tion factor NF-kB in Burkitt lymphoma cell line (BJAB)
and breast cancer cells [18-20]. VEGF levels are elevated
in the plasma of patients with CLL, where LPA
mediated protection against apoptosis in these cells
through the activation of VEGF receptors [21].
In this study, we addressed the non-STAT3 effect of
JSI-124 in leukemic cancer cells. Our results indicated
that JSI-124 treatment induced activation of JNK signal-
ing pathway leading to increased VEGF expression that
is independent of STAT3.
Methods
Materials
JSI-124 was purchased from Calbiochem Inc. and dis-
solved in DMSO at an initial stock concentration of 10
mM. Rabbit polyclonal antibodies against phosphory-
lated or total c-Jun, JNK, p38, phosphor and total Erk1/
2, XIAP and STAT3 antibodies, as well as siRNA for c-
Jun (#6203) and Stat3 siRNA I (#6580) and control
siRNA (#6201 fluorescein conjugate) were purchased
from Cell Signaling Technology, VEGF antibody was
purchased from ThermoScientific and Santa Cruz. Solu-
ble super-TRAIL was purchased from ALEXIS. Annexin
V-FITC and propidium iodide (PI) were acquired from
Pharmingen (BD Biosciences). SP600125 and SB230580
were purchased from CalBiochem. U0126 was purchased
from LC Labs, USA. All inhibitors were dissolved in
DMSO. Cells were treated with the appropriate volume
of DMSO for the vehicle control.
Cells
Burkitt lymphoma cell line -BJAB was obtained from the
American Type Culture Collection (Cedarlane Lab,
Canada) and pre-acute lymphocytic leukemia cell line,
NALM-6 was obtained from DSMZ (Braunschweig, Ger-
many). Cells were cultured and frozen down from the first
passage for future use. Cells were characterized by the cell
bank by staining with: CD3 -, CD10 +, CD19 +, CD37 -,
cyCD79a +, CD80 -, CD138 +, HLA-DR +, sm/cyIgG -,
cyIgM +, smIgM -, sm/cykappa -, sm/cylambda. I-83 was
a kind gift from Dr. Panasci (McGill University). All cell
lines were grown in RPMI 1640 medium (HyClone-Ther-
moScientific) containing 10% FCS (HyClone Thermo-
Scientific) in a humidified atmosphere (37°C; 5% CO2). All
growing cells were routinely tested for mycoplasma every
3 months. Primary B-CLL cells were isolated and main-
tained as previously described [22].
Cell lysate and Immunoblot Analysis
Lysates were prepared from BJAB, I-83, NALM-6 cells
stimulated with JSI-124 with lysis buffer (50 mM TRIS
pH = 7.4, 150 mM NaCl, 1% NP40, 0.5% sodium deoxy-
cholate, 0.1% SDS, with protease and phosphatase inhi-
bitors). The cell debris was removed by centrifugation at
13,000 × g for 5 min at 4°C, and the protein concentra-
tion was determined using the Bradford assay. After
SDS-PAGE, the proteins were transferred to nitrocellu-
lose membrane. The membranes were blocked with 5%
milk in TBS-Tween 20 solution for 1 h, followed by
overnight incubation with appropriate primary antibody
at 4°C and finally incubated for 1 h with secondary anti-
body conjugated with horseradish peroxidase (Bio-Rad).
Detection was by ECL-Western Lightning Chemilumi-
nescence reagent (Amersham Pharmacia). The blots
were stripped with Western-Re-Probe reagent (CalBio-
chem) and re-probed for b-actin to normalize for pro-
tein loading in each lane.
Transfection of BJAB, I-83 cells with siRNA
2.5 × 106 cells were used for electrophoresis (Nucleofac-
tor l Device-Lonza) with Cell line Nucleofection Kit-T-
program-O17 or C05 (Lonza) according to the
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manufacturer’s instruction. siRNA-100 nM against c-Jun
or STAT3 or non-targeting control were used. After 48
hours of transfection the cells were analyzed by FACS
for cell cycle analysis or cell lysate was prepared for
immunoblotting as described above. Transfection effi-
ciency was confirmed by transfecting 2 ug pmax-GFP or
fluorescein conjugated control siRNA using the same
condition described and then visualizing the cells using
by fluorescence microscopy.
Real-time PCR
Real-time PCR was used to assess mRNA level of VEGF
in cells that had been treated with JSI-124 for various
times. Total RNA was isolated using the RNeasy RNA
Isolation Kit (Qiagen) and 2 μg of total cellular RNA
was used as a template for reverse transcription-PCR
(RT-PCR) with random hexamers (Invitrogen). cDNA
was then used as a template for real-time PCR using
pre-designed primer sets and SYBR Green-PCR Master
Mix (BIO-RAD) according to the manufacturer’s
instructions. The following primers were used for the
real time-PCR reaction: mRNA-VEGF-F-5’-ACAAC
AAATGTGAATGCAGACC-3’ R-5’-TTTGCAGGAACA
TTTACACGTC-3’. Primers to the housekeeping gene




Nuclear extract from the cells treated with JSI-124 or
vehicle was pre-cleared with Streptavidin Agarose beads
for 30 minutes. 500 ug of pre-cleared extract was added
with 50 ng/ul Poly d(I-C), 100 nM biotin labelled DNA
probe (The probe sequence is as follows: AP1 5’-
CGCTTGATGACTCAGCCGG AA-3’) or control
probes (mAP1 5’-CGCTTGATGACTTGGCCGGAA-3’)
in binding buffer (50 mM Tris pH 7.5, 250 mM KCl, 5
mM DTT) and incubate at room temperature for 30
min. The probes were pulled down using 50 ul Strepta-
vidin-agarose. The complex was incubated for 30 min-
utes, washed 3 times with PBS and Western blotted for
transcription factors expression. Nuclear extract were
used as a positive control.
Cell death detection and Annexin V/7-AAD Staining
The cell death assay was performed as described by Ish-
dorj et al [12]. Briefly, cells (5 × 106) were collected in 5
ml tubes, centrifuged, and resuspended in 1× binding
buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl,
2.5 mM CaCl2) supplemented with annexin V-fluores-
cein isothiocyanate (BD PharMingen, Mississauga, ON)
and 2.5 μg of 7-AAD or PI (Molecular Probes, Eugene,
OR). After 15 min of incubation at room temperature in
the dark, an excess of 1× binding buffer was added to a
final volume of 500 μl. The cells were then analyzed for
FACS with Calibur flow cytometer.
Cell Cycle Analysis
Cells were fixed at least 1 hour with 70% (w/v) ice-cold
ethanol at 4°C. Cells were washed with PBS and resus-
pended in 1 mL of PBS containing 50 μg/mL PI and
500 U/mL RNase A. Following incubation for 15 min in
the dark at room temperature, cells were analyzed by
flow cytometer using the CellQuest software (Becton
Dickinson, San Jose, CA, USA). The PI fluorescence sig-
nal at FL2A peak versus the count was used to discrimi-
nate G2-M cells from G0-G1 doublets.
SupperArray Analysis
JSI-124 or DMSO treated BJAB cells were used for Sup-
perArray analysis with 96 wells Human Signal Trans-
duction PathwayFinder™ RT2 Profiler™ (SABiosciences,
QIAGEN) according to the manufacturer’s instruction.
Briefly, total RNA was isolated using the RNeasy RNA
Isolation Kit (Qiagen) and 2 μg of total RNA was used
for RT2 First Strand Kit (SABiosciences, QIAGEN). The
PCR Array was performed in 96 wells and included five
housekeeping genes. Controls are included on each
array for genomic DNA contamination, RNA quality
and general PCR performance. Data was analysis by RT2
Profiler™ PCR Array Data Analysis Software.
Statistical Analysis
All experiments were repeated at least three times and
each experiment was performed at least in duplicate.
The data were expressed as means ± SE (standard
error). Statistical analysis was performed by using Stu-
dent’s t test. The criteria for statistical significance was
p < 0.05.
Results
JSI-124 induced activation of c-Jun N-terminal kinase
(JNK) and c-Jun in B leukemic cell lines
MAPKs are serine/threonine-specific protein kinases
that respond to extracellular stimuli (mitogens, osmotic
stress, heat shock and pro-inflammatory cytokines) and
regulate various cellular activities such as gene expres-
sion, mitosis, differentiation, proliferation and cell survi-
val/apoptosis [9,10]. To identify the molecular target of
JSI-124 treatment in I-83 (CLL-like B cell line), BJAB
(Burkitt lymphoma cell line) and NALM-6 (human pre-
acute lymphocytic leukemia cell line), we examined the
effect of JSI-124 treatment on MAPK activation. We
used these cell lines because they were from B cell
derived diseases. Cells were treated with 1 μM JSI-124
or DMSO as vehicle control over a 24 hour time course.
Cell extracts were immunoblotted with antibodies
against the phosphorylated forms of MAPKs’ Erk1/2,
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p38 and JNK. This was correlated with total protein
levels. There was little change observed in phosphory-
lated p38, and Erk1/2 in BJAB cells whereas there was
an increase in p38 and Erk1/2 phosphorylation in I-83
and NALM-6 cells (Figure 1A). In contrast, there was a
significant increased in phosphorylation of JNK in a
time-dependent fashion in all three B cell derived lines.
The phosphorylation levels peaked at 6 hours following
JSI-124 treatment and then decreased over time until
they were barely detectable at the 24 hours (Figure 1B.i).
JNK is recognized as a physiologically important activa-
tor of the c-Jun transcription factor [23,24]. Therefore,
we measured the phosphorylation and protein levels of
c-Jun. At 6 hours of JSI-124 treatment, there was a sig-
nificant increase in phosphorylation and total c-Jun pro-
tein levels in all three cell lines. This was reduced at
after 24 hours treatment (Figure 1B.i). In addition, pri-
mary cells from patient with CLL were analyzed by
immunoblotting with antibodies against p-JNK/JNK and
p-c-Jun/c-Jun. Consistent with the results observed in
cell lines, p-JNK and p-c-Jun and total c-Jun levels were
significantly increased at the 6 hours’ time point with
JSI-124 treatment and reduced over time (Figure 1B.ii).
No change was observed in total JNK level. We further
determined phosphorylation status of JNK and c-Jun at
earlier time points following JSI-124 treatment. We
found no significant change in total JNK protein levels
at these earlier time points, however a significant
increase in phosphorylation of JNK was observed one
hour after treatment with JSI-124. Furthermore, a signif-
icant increase in the c-Jun protein level was observed 3
hours after JSI-124 treatment in all three cell lines (Fig-
ure 1C). This implies that activation of JNK by JSI-124
also activates c-Jun in these cells. We have previously
demonstrated that treatment with 1 μM JSI-124 induced
apoptosis and cell cycle arrest at G2 phase in BJAB, I-
83, and NALM-6 cells [7]. At this dose, we also
observed JNK and c-Jun activation (Figure 1B); therefore
we investigated whether c-Jun activation occurs at dif-
ferent dose of JSI-124. I-83, BJAB and NALM-6 cells
were treated with various doses of JSI-124 for 6 hours.
The results indicated that at a dose as low as 200 nM,
JSI-124 induced activation of c-Jun in all three cell lines
(Figure 1D). However, in BJAB cells the highest activa-
tion of c-Jun was observed at the 0.5 uM concentration.
This discrepancy in the activation of c-Jun in BJAB cells
might be due to these cells being more sensitive to JSI-
124 induced cell death compared to I-83 and NALM-6
cells after treatment. However, even after 24 hours, this
lower drug dose did not cause significant apoptosis, by
flow cytometric analysis for accumulation of sub-G1
phase and Annexin V staining (Figure 1E). This indi-
cates that JSI-124 activation of the JNK/c-Jun pathway
occurs at non-toxic JSI-124 concentrations.
JSI-124 induced apoptosis and cell cycle arrest was not
dependent on activation of JNK/c-Jun in B cell leukemia
and lymphoma cells
We have previously demonstrated that JSI-124 induced
apoptosis and cycle arrest in B-cell leukemia cells [7].
To investigate the role of the JNK/c-Jun pathway on
apoptosis and cell cycle arrest induced by JSI-124, we
pretreated I-83, BJAB, NALM-6 and primary CLL cells
with the JNK inhibitor SP600125 for one hour followed
by JSI-124 treatment for 24 hours. Cell lysates were wes-
tern blotted for phosphorylated and total c-Jun protein
levels. We found that SP600125 treatment led to
decreased expression of c-Jun protein in all three cell
lines as well as primary CLL cells (Figure 2A i and ii).
In contrast, p38 inhibitor SB230850 and Erk1/2 inhibitor
U0126, did not effect c-Jun phosphorylation or total
protein levels following JSI-124 treatment (additional file
1i and ii). Ubiquitin/proteasome system affects various
signaling pathways including JNK/c-Jun pathway [25].
To determine whether JSI-124 mediated c-Jun activation
is involved in the proteasome ubiquitin/degradation sys-
tem, cells were pretreated with MG132, a proteasome
inhibitor, followed by JSI-124 treatment. Although
MG132 itself induced c-Jun activation in all three cells,
no differences in c-Jun protein levels were found
between JSI-124 alone or in combination with MG132
treatment (additional file 1i). This data suggests that a
proteasome degradation mechanism may not be
involved in JSI-124 induced c-Jun activation. When
apoptosis was determined by AnnexinV/7AAD staining,
JSI-124 induced apoptosis in NALM-6 cells by 1% to
40% (Figure 2B). In addition, although SP600125 treat-
ment dramatically reduced c-Jun protein levels in these
cells (Figure 2Ai and ii), SP600125 had no effect on the
apoptosis induced by JSI-124 in NALM-6 cells (Figure
2B). Similarly, SP600125 did not influence the degree of
apoptosis induced in BJAB and I-83 cells by JSI-124
(data not shown). We and others have shown that JSI-
124 induced apoptosis is dependent on down-regulation
of XIAP, a member of the IAP (inhibitor of apoptosis
protein) family and serine 727 phosphorylation of
STAT3 in B-cell leukemia cells and primary CLL cells
[6,7]. However, SP600125 had no effect on the reduction
in XIAP and serine 727 phosphorylation of STAT3
levels by JSI-124 but did reduce the effect of JSI-124 on
c-Jun expression (Figure 2A). Similarly, while cell cycle
arrest was observed in all three cell lines (BJAB, I-83,
and NALM-6) following treatment with JSI-124 this was
not influenced by prior treatment with SP600125 (Figure
2C). The percentage of BJAB cells in G2/M phase
increased from 10% to 22% with JSI-124 treatment
alone and increased to 22% when the cells were pre-
treated with SP600125. In I-83 cells, the G2/M fraction
increased from 9% to 23% by JSI-124 and 22% by the
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Figure 1 JSI-124 induces phosphorylation of c-Jun in B-leukemia cells. A, and B. I-83, BJAB, NALM-6 cells were treated with 1 μM JSI-124
for a 6 and 24 hour time course. Cell lysates were used for immunoblotting for the presence of p-JNK/JNK, p-p38/p38, p-p42/44 or p42/44 and
p-c-Jun/c-Jun. Experiments were done at least in triplicate for all cells and for primary CLL cells. Representative original data are shown in Fig.1.
C. All three cell lines were treated with 1 μM JSI-124 for 6 hours. D. Cells were treated with various doses of JSI-124 for 6 hours. Phospho-and
total c-Jun levels were assessed by immunoblotting. E. BJAB, I-83, and NALM-6 cells were treated with 0.2 μM concentration of JSI-124 for 24
hour. Apoptosis was measured using flow cytometric analysis for accumulation of sub-G1 phase (upper panel) or Annexin V/7AAD staining. Data
represents 3 independent experiments. Standard error was determined on the basis of three independent experiments.
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Figure 2 JSI-124-induced apoptosis was not mediated by c-Jun activation in B-cell malignancies. A. BJAB, I-83, and NALM-6 cells were pre-
treated with 20 μM SP600125 followed by 1 μM JSI-124. Decreased levels of phospho-and total c-Jun protein levels were detected by western
blotting in the cells treated with the combination of SP600125 and JSI-124 compared to SP600125 alone. Representative original data from three
independent experiments are shown. The XIAP and STAT3proteins level, as determined by immunoblotting with antibodies against XIAP and serine
phosphor-STAT3/STAT3, did not change with this treatment B. Apoptotic cell population was measured using flow cytometric analysis for
AnnexinV/PI staining for apoptosis after 24 hour treatment with JSI-124, either alone or in combination with SP600125. DMSO-treated cells were
taken as the control. Cells that were 7-AAD-negative and Annexin V-positive were undergoing apoptosis. The percentage of cells in each quadrant
is indicated in the quadrant. Representative original data are shown. C. Cells were treated with same as above and were analyzed for cell cycle by
FACS as described in Materials and Methods. Experiments were done at least three times and representative original data are shown (* represents
significant difference of p value of < 0.05 between JSI-124 treated and untreated cells and ** represents a p value of < 0.01).
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SP600125 and JSI-124 combination (Figure 2C). Simi-
larly, JSI-124 also induced NALM-6 cell accumulation
in G2/M phase from 16% to 29% and no protection was
observed by SP600125 (31%) (Figure 2C). These results
demonstrate that the effects of JSI-124 on cell growth
are unrelated to its effects on the JNK/c-Jun pathway.
STAT3 is a transcription factor aberrantly activated in
many human solid and hematological cancers and plays
a role in oncogenesis [26]. We have previously demon-
strated that JSI-124 induces cell cycle arrest at the G2/
M phase through inhibition of STAT3 activity in human
B leukemic cells [7]. We evaluated whether JSI-124
induced c-Jun activity is dependent on STAT3 expres-
sion in the cells. To this end, STAT3 was knocked-
down using siRNA before treatment with JSI-124 and
the cell lysates were examined for JSI-124 induction of
c-Jun by immunoblot analysis in transfected and non-
transfected cells. The c-Jun protein level in cells trans-
fected with siRNA against STAT3 or non-targeting con-
trol siRNA was same as JSI-124 treated cells (Figure
3A). To control for transfection efficiency, the STAT3
level was assessed in transfected and non-transfected
cells and this confirmed a significant decrease in STAT3
in siRNA-treated cells (Figure 3A). Conversely, the
STAT3 level was unchanged in cells treated with siRNA
against c-Jun (Figure 3B). These data imply that JSI-
124-induced activation of c-Jun was not dependent on
STAT3 expression in these cells. To determine whether
JSI-124induced cell cycle arrest involves activation of c-
Jun, I-83 cells were treated with siRNA against c-Jun
following JSI-124 treatment and cells were examined for
accumulation at G2/M. In I-83 cells, the G2/M phase
fraction increased from 13% (untreated) to 27% (JSI-124
treated) and in siRNA treated cells the G2/M phase
fraction increased from 11% (siRNA-c-Jun) to 30%
(siRNA-c-Jun and JSI-124), respectively Figure 3C. This
indicates that the anti-proliferative effect of JSI-124 is
independent of c-Jun activation.
Since our results indicated that JSI-124 treatment
induced c-Jun activation through JNK phosphorylation,
we investigated whether the JNK/c-Jun pathway affects
gene transcription. To this end, we isolated the nucleus
of NALM-6 cells treated with JSI-124. The nuclear
lysates were then incubated with probes containing the
consensus DNA binding site for AP-1 or a mutated
form of the AP-1 site, and pulled down with beads as
described in the Materials and Methods. The beads
were then western blotted for the presence of c-Jun. As
a control, 10 μg of nuclear lysate from cells that were
untreated and treated with JSI-124 were western blotted
for c-Jun. We found that c-Jun binds to the AP-1 DNA
binding site following JSI-124 treatment whereas c-Jun
failed to bind to the mutant AP-1 site (Figure 3D). In
addition, untreated nuclear lysate contained a low levels
of c-Jun but after JSI-124 treatment the c-Jun levels
increased (Figure 3D). This indicates that the JSI-124
treatment increases c-Jun transcriptional activation.
JSI-124 induced VEGF expression through JNK/c-Jun
activation
One of the genes up-regulated by the JNK signaling
pathway is VEGF [17,26,27]. In Figure 4A.i, VEGF
mRNA increased at 4 hours in BJAB, I-83 and NALM-6
cells treated with JSI-124 and the levels then declined
over a 24 hour time course. VEGF protein levels in JSI-
124 treated cells increased in parallel with the VEGF
mRNA levels (Figure 4A.ii). A small increase in VEGF
protein levels was observed in primary CLL cells treated
with JSI-124 (Figure 4Aiii). To determine the relative
induction of VEGF expression compared to other stress
response genes, we treated BJAB cells with JSI-124 for 6
hours and performed super array analysis with mRNA
isolated from JSI-124 treated and control cells using a
kit from Human Signal Transduction PathwayFinder™
RT2Profiler™ (SABiosciences, QIAGEN). Consistent
with our findings above, there was an 8.7-fold increase
in c-Jun and 13.2 fold increase in VEGF-A mRNA level
in cells treated with JSI-124 (additional file 2). Further-
more, we also observed a 4.99-fold increase in c-Fos
mRNA level (additional file 2). This indicates that JSI-
124 induces VEGF expression in B leukemic cell lines.
The requirement for the JNK/c-Jun pathway to
increase VEGF expression was also evaluated. BJAB, I-
83 and NALM-6 cells were pretreated with the JNK
inhibitor, SP600125 followed by JSI-124 treatment. We
found that the pretreatment with SP600125 significantly
blocked JSI-124-induced VEGF mRNA (Figure 4Bi) and
protein (Figure 4Bii) increases in these cells. In addition,
the ability of c-Jun to regulate JNK-induced VEGF
expression was also investigated. We have determined
that SP600125 blocked c-Jun activation in B leukemia
cell lines (Figure 2A). This indicates that activation of c-
Jun may regulate VEGF expression in these cells. To
confirm the involvement of c-Jun in JSI-124 induced
VEGF expression, c-Jun was knocked-down using
siRNA and cell lysates were examined for VEGF mRNA
expression. JSI-124 treatment failed to induce VEGF
mRNA in the presence of siRNA against c-Jun whereas
the VEGF mRNA level was increased in cells transfected
with non-targeting control siRNA (Figure 4C.i). The
transfection efficiency of siRNA against c-Jun was
assessed by immunoblot analysis of c-Jun expression in
transfected and non-transfected cells. This showed a sig-
nificant decrease in c-Jun protein levels in cell trans-
fected with siRNA against c-Jun. b-actin expression was
used as the loading control (Figure 4C.ii). Moreover,
VEGF protein levels, which were increased in JSI-124
treated cells, were significantly decreased in cells
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Figure 3 JSI-124 mediated c-Jun activation was not dependent on STAT3 expression in B-cell leukemia. A and B, Cells were transfected
with siRNA-STAT or siRNA-c-Jun or siRNA non-target control. Then cells were treated with JSI-124 for additional 6 h. Cell extract was assayed for
Western blotting for STAT3 and c-Jun. Knock-down of STAT3 or c-Jun was confirmed by western blotting with antibody to STAT3 or c-Jun. C,
The same transfected cells were treated with JSI-124 for an additional 24 hours and then cells were analyzed for cell cycle analysis for G1 and
G2 phase fractions in the cells transfected with siRNA-c-Jun or non-targeting control siRNA. Standard error was determined on the basis of three
independent experiments and an asterisk represents significant difference (a p value of < 0.05) between JSI-124 treated and untreated controls.
D, Cells were stimulated with JSI-124 and nuclear extracts incubated with the AP1 probe. Pulled down with streptavidin beads, the bound
proteins were detected by SDS/polyacrylamide gel electrophoresis and western blotting. To control for specificity, a biotin-labeled scrambled
probe was used along with no probe beads control. Blots were probed with antibody to c-Jun.
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Figure 4 JSI-124 induced VEGF via activation of c-Jun. A. Increased levels of VEGF protein were detected by western blotting and mRNA by
real time PCR in I-83, BJAB, NALM-6 cells after treatment with JSI-124 for the indicated times. Representative original data from four independent
experiments are shown. B. BJAB, I-83 and NALM-6 cells were pretreated with 20 μmole/ml SP600125 for 1 hour following JSI-124 treatment for
additional 4 hours. VEGF mRNA and protein levels were detected by RT-PCR and western blotting, respectively. Standard error was determined
on the basis of three independent experiments and an asterisk represents significant difference (a p value of < 0.05) between JSI-124 alone or
pretreated with SP600125. C. in BJAB and I-83 cells c-Jun was knocked down by using siRNA for c-Jun or non-target control siRNA. Total RNA
was extracted and real time-PCR was used to detect mRNA level of VEGF. Error bars represent the standard errors for three independent
experiments. Cell extract was assayed for western blotting for VEGF. Knock-down of c-Jun was confirmed by western blotting with antibody to
c-Jun. D. NALM-6 cells were treated with 20 ng/ml VEGF-165 for 1 h and followed by JSI-124 for 24 h. The percentages of apoptotic cells were
determined by FACS analysis for sub-G1 accumulation.
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transfected with siRNA against c-Jun (Figure 4C.ii). Cells
transfected with non-targeting control siRNA showed
same amount of VEGF protein as non-transfected cells
(Figure 4C.ii). Next, we studied whether VEGF could
block JSI-124 induced apoptosis. NALM-6 cells were
pretreated with VEGF for one hour followed by JSI-124
treatment for 24 h. We observed that JSI-124 induced
apoptosis was reduced by ~25% with VEGF pretreat-
ment (Figure 4D). Taken together, these results indicate
that JSI-124 induced VEGF expression through activa-
tion of JNK/c-Jun pathway in B derived leukemia cells.
Discussion
The antitumor activity of JSI-124 has been attributed to
its effects on STAT3 signaling [1,2]. This inhibitor has
been shown to exert anti-proliferative and anti-survival
activity both in vivo and in vitro [1,3,7,26]. This indi-
cates that targeting the STAT3 pathway by JSI-124
could be an effective treatment for these cancers.
Although STAT3 is constitutively phosphorylated on
serine 727 residue in B CLL cells [7], it is upstream
mediator is not known. MAPKs Erk, but not JNK and
p38, phosphorylate serine 727 of STAT3 in vitro and in
vivo [28]. However, other study demonstrated that
MEKK7 mediated JNK1 phosphorylate serine 727 of
STAT3 [29,30]. We found no change in serine phospho-
STAT3 levels in cells treated with JNK inhibitor
SP600125 alone or in combination with JSI-124. There-
fore, the activation of JNK by JSI-124 is independent of
JSI-124 inhibition of STAT3 function in B-cell lines.
These results could be due to the differential activation
of JNKs, different types of stimuli and/or different cell
types. Furthermore, we demonstrate that JSI-124 acti-
vates the JNK/c-Jun signaling pathway and this lead to
increased VEGF expression. Although inhibition of JNK/
c-Jun reduced expression of VEGF induced by JSI-124,
we failed to detect an increase in apoptosis in the B-cell
leukemia and lymphoma cells and using VEGF receptor
inhibitor also failed to increase JSI-124 induced apopto-
sis (data not shown). Even though JNK or VEGF recep-
tor inhibition failed to block JSI-124 induced apoptosis,
JSI-124 mediated VEGF secretion and accumulation in
microenvironments might contribute to drug resistance.
Indeed, VEGF signaling has important implication for
apoptosis resistance, and enhanced survival of B CLL
cells [21]. CLL cells spontaneously secrete VEGF and
induce autocrine signaling pathway in the same cells
[31]. As STAT3 has been shown to interact with VEGF-
R1/2 in CLL [32], it is well characterized that VEGF
activation is associated with Jak-tyrosine kinase activa-
tion [12-16]. For example, in T cell lymphoma, VEGF
upregulation was associated with activation of Jak-tyro-
sine kinase and JNKs activation but was independent of
STAT3 activity [33]. This study demonstrates that JSI-
124 activates the JNK/c-Jun pathway independent of
STAT3 in B leukemic cells.
JNK was originally identified as a kinase that binds
and phosphorylates c-Jun on Ser63 and Ser73 within its
transcriptional activation domain [9,10]. JNK is activated
in response to various stress stimuli such as environ-
mental stress, including UV, osmotic shock, inflamma-
tory cytokines and chemotherapic drugs [9,10,34]. The
studies using JNK knockout mice suggested its impor-
tant role in leukemia and skin tumorigenesis and insulin
resistant diabetes [34,35]. JNK phosphorylates diverse
substrates but one important function is the ability to
phosphorylate c-Jun and induce AP-1 dependent tran-
scription [10,34]. When phosphorylated, c-Jun forms
either monodimer or heterodimer with c-Fos. The het-
erodimer c-Jun/c-Fos binds to the AP-1 DNA binding
sites more efficiently that the c-Jun monodimer does
[10,34]. In this study we found that JSI-124 induced
JNK mediated c-Jun phosphorylation and its transcrip-
tional activation for binding to AP-1-DNA site. In addi-
tion, we also observed that JSI-124 induced activation of
Fos mRNA. Therefore we speculate that JSI-124 might
be inducing heterodimer formation of c-Jun/c-Fos. This
will be elucidated in further studies. More interestingly,
we also observed that even nontoxic dose of JSI-124
caused constitutive activation of c-Jun suggesting JSI-
124 activation of the JNK/c-Jun pathway is one of the
earliest responses to JSI-124 treatments in these cells.
It is known that an important factor involved in VEGF
induction is JNK signaling [36,37] and JNK induces c-
Jun phosphorylation at the VEGF promoter [37].
Genetic or pharmacological inhibition of JNK/c-Jun
reduces VEGF expression. In detail, we found that JSI-
124 selectively up-regulated VEGF expression in
response to acute exposure (3-6 hours) and this was
inhibited by JNK inhibitor SP600125 or siRNA against
c-Jun in B cell tumors. Consistent with our finding, it
was shown before that JNKs induce VEGF expression by
increasing c-Jun/AP1 activity in T-cell lymphomas [33].
On the other hand, VEGF has been found to be one
of the key regulators of angiogenesis in many cancers,
including chronic lymphocytic leukemia [21,27,38]. Pre-
viously we have shown that regulation of VEGF expres-
sion is controlled by JNK and NFB activation in BJAB
cells [21]. This leads to activation of VEGF receptors
and cell survival in B-cell derived malignancies including
CLL. Genotoxic stress has been found to induce VEGF
expression. For example, human melanoma cells treated
with the antineoplastic drug, dacarbazine, produces an
increase in secreted VEGF [39]. Also, ultraviolet irradia-
tion or photodynamic therapy can increase tumor cell
VEGF secretion from keratinocytes or prostate cancer
cells respectively [40,41]. It has also been shown that
some tumors derived from c-Jun-transformed cells
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exhibit a higher level of formation of functional micro-
vascular networks than those derived from other onco-
genes [42].
Consclusions
Our study indicates that, in contrast to its inhibition of
STAT3, JSI-124 activates the JNK signaling pathway
leading to VEGF expression. This suggests that JSI-124
is inducing a stress response in B leukemia cells poten-
tially leading to increased angiogenesis. Future studies
will be aimed to understand whether inhibition of VEGF
may be targeted therapeutically to enhance JSI-124-
induced cell death in CLL and B-cell malignancy. Taken
together, our study provides new insight into the mole-
cular effects of this potentially important new che-
motherapeutic agent.
Additional material
Additional file 1: p38 and Erk1/2 signaling was not involved in JSI-
124 mediated c-Jun activation. BJAB, I-83, and NALM-6 cells were
pretreated with 20 μM SP230850 or U0126 or 5 uM MG132 following 1
μM JSI-124 treatment. c-Jun protein levels were detected by western
blotting Representative original data from three independent
experiments are shown.
Additional file 2: Supper Array analysis. BJAB cell were treated by JSI-
124 for 6 hours. Total RNA was extracted as described in Materials and
Methods. 84 genes Super Array analysis was carried out by using kit for
Human Signal Transduction PathwayFinder™™ RT2Profiler™™ Human
Signal Transduction PathwayFinder™™ RT2Profiler™™ (SABiosciences).
Acknowledgements
This study was supported by a grant from the Leukemia and Lymphoma
Society of Canada and CancerCare Manitoba Foundation. SBG is a Manitoba
Research Chair supported by the Manitoba Health Research Council (MHRC)
and GI held a fellowship from MHRC. Finally, we would like to thank all the
patients who contributed blood samples to the Manitoba Tumour Bank for
making this research possible. Manitoba Tumor Bank is a member of the
Canadian Tumor Repository Network (CTRNet).
Author details
1Manitoba Institute of Cell Biology, Winnipeg, MB, Canada. 2Department of
Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB,
Canada. 3Department of Internal Medicine, University of Manitoba, Winnipeg,
MB, Canada.
Authors’ contributions
GI carried out the experiments and drafted the manuscript. JBJ participated
in the collection of patients’ samples and in the design and coordination of
the study. SBG conceived of the study, and participated in its design and
coordination. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 January 2011 Accepted: 24 June 2011
Published: 24 June 2011
References
1. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM: Discovery of
JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and
activator of transcription 3 signaling pathway inhibitor with potent
antitumor activity against human and murine cancer cells in mice.
Cancer Research 2003, 63(6):1270-9.
2. Chen JC, Chiu MH, Nie RL, Cordell GA, Qiu SX: Cucurbitacins and
cucurbitane glycosides: structures and biological activities. Natural
Product Reports 2005, 22(3):386-99.
3. Lee DH, Iwanski GB, Thoennissen NH: Cucurbitacin: ancient compound
shedding new light on cancer treatment. Scientific World Journal 2010,
10:413-8.
4. Jing N, Tweardy DJ: Targeting Stat3 in cancer therapy. Anticancer Drugs
2005, 16(6):601-7.
5. Molavi O, Ma Z, Hamdy S, Lai R, Lavasanifar A, Samuel J: Synergistic
antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory
agent JSI-124 in a mouse melanoma tumor model. Immunology and Cell
Biology 2008, 86(6):506-14.
6. Su Y, Li G, Zhang X, Gu J, Zhang C, Tian Z, Zhang J: JSI-124 inhibits
glioblastoma multiforme cell proliferation through G(2)/M cell cycle
arrest and apoptosis augment. Cancer Biology and Therapy 2008,
7(8):1243-9.
7. Ishdorj G, Johnston JB, Gibson SB: Inhibition of constitutive activation of
STAT3 by curcurbitacin-I (JSI-124) sensitized human B-leukemia cells to
apoptosis. Molecular Cancer Therapeutics 2010, 9(12).
8. Graness A, Poli V, Goppelt-Struebe M: STAT3-independent inhibition of
lysophosphatidic acid-mediated upregulation of connective tissue
growth factor (CTGF) by cucurbitacin I. Biochemical Pharmacology 2006,
72(1):32-41.
9. Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell 2000,
103(2):239-52.
10. Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature
2001, 410:37-40.
11. Rosen LS: VEGF-targeted therapy: therapeutic potential and recent
advances. Oncologist 2005, 10(6):382-91.
12. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature
2000, 407(6801):249-57.
13. Chiarug V, Ruggiero M, Magnelli L: Angiogenesis and the unique nature
of tumor matrix. Molecular Biotechnology 2002, 21(1):85-90.
14. Chien MH, Ku CC, Johansson G, Chen MW, Hsiao M, Su JL, Inoue H, Hua KT,
Wei LH, Kuo ML: Vascular endothelial growth factor-C (VEGF-C) promotes
angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/
JNK/AP-1 pathway. Carcinogenesis 2009, 30(12):2005-13.
15. Molica S: Angiogenesis in B-cell chronic lymphocytic leukemia: methods
of study, clinical significance and prognostic implications. Leukemia and
Lymphoma 2001, 42(4):603-7.
16. Lee J, Park SY, Lee EK, Park CG, Chung HC, Rha SY, Kim YK, Bae GU, Kim BK,
Han JW, Lee HY: Activation of hypoxia-inducible factor-1alpha is
necessary for lysophosphatidic acid-induced vascular endothelial growth
factor expression. Clinical Cancer Research 2006, 12(21):6351-8.
17. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand Holash SJ: Vascular-
specific growth factors and blood vessel formation. Nature 2000,
407(6801):242-8.
18. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Lovato P, Labuda T,
Eriksen KW, Zhang Q, Becker JC, Ødum N: Jak3-and JNK-dependent
vascular endothelial growth factor expression in cutaneous T-cell
lymphoma. Leukemia 2006, 20(10):1759-66.
19. Kumar SA, Hu X, Brown M, Kuschak B, Hernandez TA, Johnston JB,
Gibson SB: Lysophosphatidic acid receptor expression in chronic
lymphocytic leukemia leads to cell survival mediated though vascular
endothelial growth factor expression. Leukemia and Lymphoma 2009,
50(12):2038-48.
20. Shibata A, Nagaya T, Imai T, Funahashi H, Nakao A, Seo H: Inhibition of NF-
kappaB activity decreases the VEGF mRNA expression in MDA-MB-231
breast cancer cells. Breast Cancer Research and Treatment 2002,
73(3):237-43.
21. Hu X, Mendoza FJ, Sun J, Banerji V, Johnston JB, Gibson SB: Lysophosphatidic
acid (LPA) induces the expression of VEGF leading to protection against
apoptosis in B-cell derived malignancies. Cell Signaling 2008, 20(6):1198-208.
22. Ishdorj G, Graham BA, Hu X, Chen J, Johnston JB, Fang X, Gibson SB:
Lysophosphatidic acid protects cancer cells from histone deacetylase
(HDAC) inhibitor-induced apoptosis through activation of HDAC. Journal
of Biological Chemistry 2008, 283(24):16818-29.
23. Heasley LE, Han SY: JNK regulation of oncogenesis. Molecular Cells 2006,
21(2):167-73.
Ishdorj et al. BMC Cancer 2011, 11:268
http://www.biomedcentral.com/1471-2407/11/268
Page 11 of 12
24. Jaeschke A, Karasarides M, Ventura JJ, Ehrhardt A, Zhang C, Flavell RA,
Shokat KM, Davis RJ: JNK2 is a positive regulator of the cJun transcription
factor. Molecular Cell 2006, 23(6):899-911.
25. Fuchs SY, Fried VA, Ronai Z: Stress-activated kinases regulate protein
stability. Oncogene 1998, 17:1483-90.
26. Lin TS, Mahajan S, Frank DA: STAT signaling in the pathogenesis and
treatment of leukemias. Oncogene 2000, 19(21):2496-504.
27. Kuida K, Boucher DM: Functions of MAP Kinases: Insights from Gene-
Targeting Studies. J Biochem 2004, 135(6):653-656.
28. Chung J, Uchida E, Grammer TC, Blenis J: STAT3 serine phosphorylation
by ERK-dependent and-independent pathways negatively modulates its
tyrosine phosphorylation. Mol Cell Biol 1997, 17(11):6508-16.
29. Lim CP, Cao X: . Serine phosphorylation and negative regulation of Stat3
by JNK. J Biol Chem 1999, 274:31055-31061.
30. Nitta RT, Del Vecchio CA, Chu AH, Mitra SS, Godwin AK, Wong AJ: The role
of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung
carcinoma tumorigenesis. Oncogene 2011, 30(2):234-44.
31. Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW,
Hanson CA, Jelinek DF: B-CLL cells are capable of synthesis and secretion
of both pro-and anti-angiogenic molecules. Leukemia 2002, 16(5):911-9.
32. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE: VEGF
receptors on chronic lymphocytic leukemia (CLL) B cells interact with
STAT 1 and 3: implication for apoptosis resistance. Leukemia 2005,
19(4):513-23.
33. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Lovato P, Labuda T,
Eriksen KW, Zhang Q, Becker JC, Ødum N: Jak3-and JNK-dependent
vascular endothelial growth factor expression in cutaneous T-cell
lymphoma. Leukemia. 200 2006, 20(10):1759-66.
34. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M,
Hotamisligil GS: A central role for JNK in obesity and insulin resistance.
Nature 2002, 420(6913):333-6.
35. Platanias L: Map kinase signaling pathways Map kinase signaling
pathways and hematologic malignancies. Blood 2003, 101:4667-4679.
36. Berra E, Pagès G, Pouysségur J: MAP kinases and hypoxia in the control of
VEGF expression. Cancer and Metastasis Reviews 2000, 19(1-2):139-45.
37. Guma M, Rius J, Duong-Polk KX, Haddad GG, Lindsey JD, Karin M: Genetic
and pharmacological inhibition of JNK ameliorates hypoxia-induced
retinopathy through interference with VEGF expression. Proceedings of
the National Academy of Sciences 2009, 106(21):8760-5.
38. Ellis LM, Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumour
activity. Nature Reviews Cancer 2008, 8(8):579-91.
39. Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M: Dacarbazine causes
transcriptional up-regulation of interleukin 8 and vascular endothelial
growth factor in melanoma cells: a possible escape mechanism from
chemotherapy. Molecular Cancer Therapeutics 2003, 2(8):753-63.
40. Solban N, Selbo PK, Sinha AK, Chang SK, Hasan T: Mechanistic
investigation and implications of photodynamic therapy induction of
vascular endothelial growth factor in prostate cancer. Cancer Research
2006, 66(11):5633-40.
41. Yano K, Kadoya K, Kajiya K, Hong YK, Detmar M: Ultraviolet B irradiation of
human skin induces an angiogenic switch that is mediated by
upregulation of vascular endothelial growth factor and by
downregulation of thrombospondin-1. British Journal Dermatology 2005,
152(1):115-21.
42. Kraemer M, Tournaire R, Dejong V, Montreau N, Briane D, Derbin C,
Binétruy B: Rat embryo fibroblasts transformed by c-Jun display highly
metastatic and angiogenic activities in vivo and deregulate gene
expression of both angiogenic and antiangiogenic factors. Cell Growth
and Differentiation 1999, 10(3):193-200.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/268/prepub
doi:10.1186/1471-2407-11-268
Cite this article as: Ishdorj et al.: Cucurbitacin-I (JSI-124) activates the
JNK/c-Jun signaling pathway independent of apoptosis and cell cycle
arrest in B Leukemic Cells. BMC Cancer 2011 11:268.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ishdorj et al. BMC Cancer 2011, 11:268
http://www.biomedcentral.com/1471-2407/11/268
Page 12 of 12
